Sarepta is currently testing SRP-9001 in the placebo-controlled EMBARK study, which aims to enrol 120 boys with DMD aged four to seven and is due to read out in the latter half of 2023.

As a result, higher-potency steroids should be avoided in children (Paller et al., 2005). Local adverse effects of topical steroids include striae, skin atrophy, telangiectasias, perioral ...

This penem inhibitor was used for co-crystallization of the Δ2–75 SPase. [43] The co-crystal structure revealed that the side chain methyl group (C16) of the penem, previously reported to be ...